Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study
MT newswire2026/10/07 11:3207:32 AM EDT, 10/07/2026 (MT Newswires) -- Pulse Biosciences (PLSE) said Wednesday that its Nanopulse-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites, three months ahead of schedule. The study is evaluating the safety and effectiveness of the nPulse Cardiac Catheter System in patients with drug-resistant, symptomatic paroxysmal atrial fibrillation, the company said. Primary endpoints will be assessed at six and 12 months after ablation, it added. Pulse Biosciences said it expects to present pivotal data at a future medical society conference.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
